PMID- 34397833
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 31
DP  - 2021 Aug 6
TI  - A rapid response of lung squamous cell carcinoma following treatment with 
      sintilimab combined with recombinant humane endostatin injection and 
      nab-paclitaxel in an elderly patient: A case report.
PG  - e26801
LID - 10.1097/MD.0000000000026801 [doi]
LID - e26801
AB  - RATIONALE: At present, the prognosis of patients with giant lung squamous cell 
      carcinoma (LSCC) is poor, and there is no safe and effective treatment for 
      elderly patients with large LSCC. PATIENT CONCERNS: Here, we reported a 
      77-year-old man admitted to the hospital with cough for 3 months and significant 
      chest pain. Computed tomography (CT) imaging showed a large mass in the left lung 
      with pleural effusion. DIAGNOSES: Chest CT scan revealed a 12.5 cm x 7.3 cm mass 
      in the left upper lobe adjacent to the pulmonary vein, with left pleural 
      effusion. Pulmonary tumor markers were significantly elevated, and CT-guided 
      percutaneous lung mass biopsy specimens showed LSCC. INTERVENTIONS: After 
      diagnosis, the patient was treated with sintilimab combined with endostar and 
      nab-paclitaxel. After 2 cycles of treatment, the lung mass in the patient shrank 
      rapidly and the clinical symptoms were relieved. OUTCOMES: The patient's tumor 
      dramatically shrank, and the pleural effusion was decreased after 4 cycles of 
      treatment without any adverse effects. Meanwhile, the high-level tumor marker 
      resumed normal. LESSONS: Sintilimab combined with endostar and nab-paclitaxel may 
      be a good treatment option for lung squamous cell cancer, especially for that in 
      elderly patients.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Fang, Yueyu
AU  - Fang Y
AD  - Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of 
      Jiangsu Province Hospital, Nanjing, People's Republic of China.
FAU - Sun, Hui
AU  - Sun H
AD  - Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of 
      Jiangsu Province Hospital, Nanjing, People's Republic of China.
FAU - Chen, Yi
AU  - Chen Y
AD  - Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of 
      Jiangsu Province Hospital, Nanjing, People's Republic of China.
FAU - Jiang, Nanyuan
AU  - Jiang N
AD  - Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of 
      Jiangsu Province Hospital, Nanjing, People's Republic of China.
FAU - Ji, Lianhua
AU  - Ji L
AD  - Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of 
      Jiangsu Province Hospital, Nanjing, People's Republic of China.
FAU - Shi, Junfeng
AU  - Shi J
AUID- ORCID: 0000-0001-6424-3149
AD  - Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Endostatins)
RN  - 0 (Recombinant Proteins)
RN  - 8FU7FQ8UPK (sintilimab)
RN  - GVG18ZDN65 (endostar protein)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Aged
MH  - Albumins/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Antineoplastic Agents/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Biopsy/methods
MH  - *Carcinoma, Squamous Cell/pathology/physiopathology
MH  - Endostatins/*administration & dosage
MH  - Humans
MH  - Lung/diagnostic imaging/pathology
MH  - *Lung Neoplasms/pathology/physiopathology
MH  - Male
MH  - Neoplasm Staging
MH  - Paclitaxel/*administration & dosage
MH  - *Pleural Effusion/diagnostic imaging/etiology
MH  - Recombinant Proteins/*administration & dosage
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
MH  - Tumor Burden
PMC - PMC8341334
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/08/17 06:00
MHDA- 2021/09/03 06:00
PMCR- 2021/08/06
CRDT- 2021/08/16 12:50
PHST- 2021/04/06 00:00 [received]
PHST- 2021/07/12 00:00 [accepted]
PHST- 2021/08/16 12:50 [entrez]
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2021/08/06 00:00 [pmc-release]
AID - 00005792-202108060-00046 [pii]
AID - MD-D-21-02543 [pii]
AID - 10.1097/MD.0000000000026801 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Aug 6;100(31):e26801. doi: 
      10.1097/MD.0000000000026801.